296 Results
Sort By:
Published on October 18, 2024
Phenomix Sciences, a biotech focusing on obesity phenotyping and biomarker testing, will partner with genetic testing and counseling provider InformedDNA to provide targeted obesity treatment based on underlying biology. Obesity is a very heterogeneous condition that can manifest for many different reasons. The approval of Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) for…
Published on September 11, 2024
The obesity drug liraglutide (Novo’s Saxenda) is safe and effective in children aged 6 to 12 years, according to results of the SCALE Kids trial. The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid this week. The study was…
Published on September 4, 2024
People with obesity have a higher risk of contracting SARS-CoV-2, according to a new study led by researchers at Brigham and Women’s Hospital and Harvard Medical School. They used electronic medical record data on over 70,000 patients from their own hospital system. Obesity is known to predict worse outcomes and…
Published on July 2, 2024
Research led by Baylor College of Medicine and the University of Cambridge has discovered mutations in the gene TRPC5, located on the X chromosome, that can cause obesity and postpartum depression. This gene is expressed in the hypothalamus in the brain and is thought to impact a number of different…
Published on June 25, 2024
Two separate Phase III clinical trials have shown that the diabetes and obesity drug tirzepatide led to significant decreases in the in the number of breathing interruptions during sleep of patients with obstructive sleep apnea (OSA), setting it up as potentially the first medication to treat the disorder. The results…
Published on June 21, 2024
A new genetic variant linked with obesity has been discovered, which could help explain weight gain for hundreds of thousands of people worldwide. The researchers believe their findings may unlock new obesity treatments and are hoping to run a trial to see if a widely available, low-cost thyroid medication might…
Published on June 5, 2024
A report published in 2023, estimates that over 40% of adults in the U.S. have obesity, defined as a body mass index (BMI) of over 30 kg/m2. While not everyone in this group is unwell, there is no doubt that obesity increases the risk of associated health conditions such as…
Published on April 3, 2024
A study led by the Navarra Institute for Health Research in Spain shows that specific gut bacteria are predictive of obesity, but that the species involved differ between men and women. Paula Aranaz, a researcher at the Center for Nutrition Research at the University of Navarra, will present the research…
Published on April 1, 2024
A population-based study from Sweden indicates that children and teenagers who were overweight or have obesity are more likely to have high blood pressure in later adult years from 50 to 64 years of age. The research, to be presented at the upcoming European Congress on Obesity (ECO) next month…
Published on March 29, 2024
Childhood obesity more than doubles the risk of later developing multiple sclerosis (MS), new research shows. The study will be presented at this year’s European Congress on Obesity in Venice, Italy (May 12–15) presented by Claude Marcus and Emilia Hagman, the Karolinska Institute, and colleagues. Pediatric obesity is associated with…
Published on March 13, 2024
Scientists at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have shed light on the far-reaching consequences of maternal obesity, particularly its role in predisposing unborn children to liver diseases and potentially liver cancer. Obesity, an epidemic looming large in many developed nations, not only poses a significant…
Published on January 17, 2024
Individuals with obesity are more likely to have a benign blood condition that often precedes multiple myeloma, according to new research to be published in Blood Advances. People who are physically active, meanwhile, are less likely to have this condition, even if they are obese. Smoking and too little sleep…
Published on December 22, 2023
Fauna Bio has announced a multi-year agreement with Eli Lilly and Company to apply Fauna’s Convergence artificial intelligence (AI) platform for preclinical drug discovery in obesity. Fauna’s unique platform analyzes data collected from animal hibernation biology (and other extreme adaptations) to identify drug targets for humans. The terms of this deal…
Published on December 4, 2023
Roche announced today it is acquiring Carmot Therapeutics for $2.7B up front with potential milestone payments of $400M. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins to treat obesity, as well as a number of preclinical programs. Carmot’s lead program is a Phase-II ready, dual GLP-1/GIP receptor agonist…
Published on October 11, 2023
Heart health experts are declaring the overlapping effects of obesity, Type 2 diabetes, chronic kidney disease, and cardiovascular disease as a new syndrome—cardiovascular-kidney-metabolic syndrome, or CKM. This change, they say, is prompting rethinking of how they predict long-term cardiovascular risks. A presidential advisory from the American Heart Association (AHA), published Monday in the…